Susan Froshauer served as President and CEO of CURE (now BioCT) from 2013 through Oct 2017. BioCT provides education, entrepreneurial resources, and advocates on behalf of the bioscience industry in Connecticut.

Today, she is VP of CURE Collaborations, LLC, a leader of the CURE Commons accelerator programs, and an Entrepreneur in Residence at Yale’s Office of Cooperative Research. She is also a board member of Carogen, LambdaVision, Bioxiness, Thames River Innovation Partners.

Earlier in her career she was a co-founder and CEO of Rib-X Pharmaceuticals (now Melinta). During her 11 year tenure she led the company through $160mm of investment and development of novel antibiotic treatments.

Susan received a Ph.D. in Microbiology and Molecular Genetics from Harvard University and a B.A. from Connecticut College. Earlier in her career she served as a Research Scientist and Licensing Executive at Pfizer.

Please see the Parking Map for parking directions.